Inotuzumab ozogamicin

CaLiGraph

Property	Value
rdf:type	Wyeth brand owl:NamedIndividual Antibody-drug conjugate Pfizer brand Therapeutic monoclonal antibody Monoclonal antibody for tumors Drug granted breakthrough therapy designation
rdfs:label	Inotuzumab ozogamicin
owl:sameAs	dbr:Inotuzumab_ozogamicin
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/Celltech http://en.wikipedia.org/wiki/Antibody-drug_conjugate http://en.wikipedia.org/wiki/Category:Antibody-drug_conjugates http://en.wikipedia.org/wiki/Category:Pfizer_brands http://en.wikipedia.org/wiki/List_of_drugs:_Im%E2%80%93In http://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies http://en.wikipedia.org/wiki/First-in-class_medication http://en.wikipedia.org/wiki/Monoclonal_antibody_therapy http://en.wikipedia.org/wiki/List_of_drugs_granted_breakthrough_therapy_designation http://en.wikipedia.org/wiki/Category:Monoclonal_antibodies_for_tumors http://en.wikipedia.org/wiki/Category:Wyeth_brands
skos:prefLabel	Inotuzumab ozogamicin
skos:altLabel	inotuzumab ozogamicin
clgo:alternativeName	Besponsa
clgo:casNumber	635715-01-4
clgo:drugbank	DB05889
clgo:fdaUniiCode	P93RUU11P7
clgo:kegg	D08933
clgo:medlinePlus	a617041

About: clgr:Inotuzumab_ozogamicin